Free Trial

Oxford Biomedica (OXB) Competitors

Oxford Biomedica logo
GBX 600 +8.00 (+1.35%)
As of 10/24/2025 12:03 PM Eastern

OXB vs. GNS, ONT, ERGO, SLN, PRTC, HZD, AVCT, VRP, FARN, and ARIX

Should you be buying Oxford Biomedica stock or one of its competitors? The main competitors of Oxford Biomedica include Genus (GNS), Oxford Nanopore Technologies (ONT), Ergomed (ERGO), Silence Therapeutics (SLN), PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Avacta Group (AVCT), Verona Pharma plc (VRP.L) (VRP), Faron Pharmaceuticals Oy (FARN), and Arix Bioscience (ARIX). These companies are all part of the "biotechnology" industry.

Oxford Biomedica vs. Its Competitors

Oxford Biomedica (LON:OXB) and Genus (LON:GNS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

Oxford Biomedica presently has a consensus target price of GBX 558, suggesting a potential downside of 7.00%. Genus has a consensus target price of GBX 2,900, suggesting a potential upside of 14.62%. Given Genus' stronger consensus rating and higher possible upside, analysts clearly believe Genus is more favorable than Oxford Biomedica.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oxford Biomedica
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Genus
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Oxford Biomedica had 3 more articles in the media than Genus. MarketBeat recorded 4 mentions for Oxford Biomedica and 1 mentions for Genus. Oxford Biomedica's average media sentiment score of 1.54 beat Genus' score of 0.96 indicating that Oxford Biomedica is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oxford Biomedica
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Genus
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Oxford Biomedica has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Genus has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.

32.4% of Oxford Biomedica shares are held by institutional investors. Comparatively, 63.4% of Genus shares are held by institutional investors. 41.9% of Oxford Biomedica shares are held by insiders. Comparatively, 0.7% of Genus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Genus has a net margin of 1.18% compared to Oxford Biomedica's net margin of -145.98%. Genus' return on equity of 1.41% beat Oxford Biomedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford Biomedica-145.98% -202.50% -12.67%
Genus 1.18%1.41%3.31%

Genus has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford Biomedica£151.21M4.77-£143.51M-£36.22-16.57
Genus£672.80M2.49£7.87M£28.9087.54

Summary

Genus beats Oxford Biomedica on 10 of the 16 factors compared between the two stocks.

Get Oxford Biomedica News Delivered to You Automatically

Sign up to receive the latest news and ratings for OXB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OXB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OXB vs. The Competition

MetricOxford BiomedicaBiotechnology IndustryMedical SectorLON Exchange
Market Cap£688.78M£220.37M£6.21B£2.66B
Dividend Yield4.57%3.81%5.72%5.35%
P/E Ratio-16.573.2831.60400.09
Price / Sales4.775,399.00595.0698,316.31
Price / Cash3.0113.1937.2527.90
Price / Book8.8690.1312.057.26
Net Income-£143.51M-£90.99M£3.34B£5.88B
7 Day Performance1.73%0.72%1.94%1.07%
1 Month Performance9.83%5.76%6.88%1.36%
1 Year Performance34.83%488.85%56.06%121.87%

Oxford Biomedica Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OXB
Oxford Biomedica
1.6045 of 5 stars
GBX 600
+1.4%
GBX 558
-7.0%
+34.8%£688.78M£151.21M-16.57891Positive News
GNS
Genus
1.9558 of 5 stars
GBX 2,615
+0.6%
GBX 2,900
+10.9%
+22.5%£1.73B£672.80M90.48480
ONT
Oxford Nanopore Technologies
1.7504 of 5 stars
GBX 144.20
+0.2%
GBX 245
+69.9%
-0.3%£1.39B£204.69M-9.741,281Positive News
ERGO
Ergomed
N/AN/AN/AN/A£701.00M£152.09M4,641.386
SLN
Silence Therapeutics
N/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading Volume
PRTC
PureTech Health
N/AGBX 133.80
+0.3%
GBX 455
+240.1%
-12.4%£323.37M£6.17M7.87300
HZD
Horizon Discovery Group plc (HZD.L)
N/AN/AN/AN/A£302.98M£54.63M-33.55416
AVCT
Avacta Group
1.8708 of 5 stars
GBX 65
+2.4%
GBX 99
+52.3%
+13.9%£265.37M£113K-3.70120
VRP
Verona Pharma plc (VRP.L)
N/AN/AN/AN/A£228MN/A-1.6822Gap Up
FARN
Faron Pharmaceuticals Oy
N/AGBX 177.70
+1.5%
N/A+3.4%£198.94MN/A-6.5834Positive News
High Trading Volume
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919

Related Companies and Tools


This page (LON:OXB) was last updated on 10/26/2025 by MarketBeat.com Staff
From Our Partners